1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Elderly Hodgkin lymphoma At MSKCC From 1994-2008: Characteristics, outcome and risk factor analysis in 133 patients
    Meeting Abstract

    Word, Z. H.; Maragulia, J. C.; Walkley, J.; Smith, D. R.; Hamlin, P.
    Blood (2011)

    Fulltext@MSK | Save
  • Induction of megakaryocyte polyploidization in combination with JAK inhibition as a novel therapeutic strategy for myeloproliferative neoplasms
    Meeting Abstract

    Wen, Q. J.; Goldenson, B.; Malinge, S.; Koppikar, P.; Levine, R. L.; Tefferi, A.; Crispino, J.
    Blood (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition targets JAK2 and is highly effective in CRLF2-rearranged acute lymphoblastic leukemia
    Meeting Abstract

    Weigert, O.; Bird, L.; Kopp, N.; Lane, A. A.; Chapuy, B.; van Bodegom, D.; Marubayashi, S.; Yoda, A.; Romanet, V.; Murakami, M.; more...
    Blood (2011)

    Fulltext@MSK | Save
  • Anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab followed by stem cell transplantation in relapsed/refractory DLBCL patients: Safety and efficacy
    Meeting Abstract

    Wagner-Johnston, N.; Goy, A.; Rodriguez, M. A.; Ehmann, C.; Hamlin, P.; Radford, J.; Thieblemont, C.; Suh, C.; Sweetenham, J.; Jiang, Y.; more...
    Blood (2011)

    Fulltext@MSK | Save
  • Regulation of AML1/RUNX1 function by protein arginine methyltransferase 4 (PRMT4) in myeloid differentiation
    Meeting Abstract

    Vu, L. P.; Zhao, X. Y.; Perna, F.; Nimer, S. D.
    Blood (2011)

    Fulltext@MSK | Save
  • Randomized phase HI trial of (131)iodine-tositumomab (bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS)
    Meeting Abstract

    Vose, J. M.; Carter, S. L.; Burns, L. J.; Ayala, E.; Press, O. W.; Moskowitz, C. H.; Stadtmauer, E. A.; Mineishi, S.; Ambinder, R. F.; Fenske, T. S.; more...
    Blood (2011)

    Fulltext@MSK | Save
  • Genetics of intestinal graft-versus-host disease
    Meeting Abstract

    van den Brink, M. R. M.
    Blood (2011)

    Fulltext@MSK | Save
  • WT1-specific immune responses in patients with high-risk multiple myeloma undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation followed by donor lymphocyte infusions
    Meeting Abstract

    Tyler, E.; Jungbluth, A. A.; O'Reilly, R. J.; Koehne, G.
    Blood (2011)

    Fulltext@MSK | Save
  • D-dimer variability in the postpartum period
    Meeting Abstract

    Tamari, R.; Billett, H. H.; Cohen, H.
    Blood (2011)

    Fulltext@MSK | Save
  • Final results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene (Bex) in advanced cutaneous T-cell lymphoma (CTCL)
    Meeting Abstract

    Straus, D. J.; Duvic, M.; Horwitz, S. M.; Hymes, K. B.; Goy, A.; Hernandez-Ilizaliturri, F. J.; Feldman, T.; Wegner, B.; Myskowski, P.
    Blood (2011)

    Fulltext@MSK | Save